Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated pediatric cancer models.
- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated pediatric cancer models.
- As a global partner, Charles River is offering clients access to this collection.
- By offering this collection, Charles River is combining decades of oncology research experience with a powerful tool that will better guide critical investigative decisions.
- With a global infrastructure and deep scientific bench, Charles River is positioned to support programs from basic science to IND submission.